<DOC>
	<DOCNO>NCT01124617</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety tapentadol extended-release ( ER ) tablets Japanese participant moderate severe chronic ( last long time ) pain due painful diabetic peripheral neuropathy ( pain extremity relate diabetes-induced nerve damage ) postherpetic neuralgia ( pain last condition heal ) .</brief_summary>
	<brief_title>A Phase 2 Study Tapentadol Extended-Release ( JNS024ER ) ) Japanese Participants With Chronic Pain Due Diabetic Neuropathic Pain Postherpetic Neuralgia</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , multi-center ( one hospital medical school team work medical research study ) , double-blind ( neither physician participant know name assigned drug ) , placebo-control ( participant randomly assign test treatment identical-appearing treatment contain test drug ) , parallel-group ( group participant treat time ) comparison study Japanese participant chronic pain due painful diabetic peripheral neuropathy postherpetic neuralgia . The duration study 14 week . The study consist 3 part : Screening ( 1 Week study commences Day 1 ) ; Treatment ( 12 week include titration period [ initiation study treatment determination individual 's maintenance dose ] maintenance period [ completion titration period to12 week ] ) ; Follow-up ( 1 Week ) . Tapentadol hydrochloride ER oral tablet match placebo administer twice daily 12 week . Efficacy participant primarily evaluate Numerical Rating Scale ( NRS ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Participants chronic pain due painful diabetic neuropathy postherpetic neuralgia continue least 12 week consent Participants adjuvant analgesic ( antidepressant , antiepileptic diabetic peripheral neuropathy drug ) nonopioid treatment dissatisfied current treatment ( sense efficacy and/or safety ) least consecutive 14 day 12 week consent Participants experience treatment conventional opioids , except follow case : Short term use opioid analgesic treatment postoperative acute pain 30 day consent ; temporal use codeine phosphate dihydrocodeine phosphate purpose pain relief ( example , antitussive ) 2 day consent Mean pain intensity score great equal 5 11point Numerical Rating Scale 48 hour consent Investigator Subinvestigator considers participant treat opioid analgesic HbA1c within 4 week consent less equal 11percent ( participant diabetic neuropathic pain ) Participants treat treated monoamine oxidase inhibitor within 14 day consent Current history epilepsy convulsive disorder hypersensitivity opioid analgesic Suggested intracranial hypertension ( example , traumatic encephalopathy ) Participants complicate condition uncontrolled clinically significant arrhythmia , neuropsychiatric disorder Participants moderately severely impaired hepatic function , severely impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>Diabetic Neuropathic Pain</keyword>
	<keyword>Neuralgia , Postherpetic</keyword>
	<keyword>Tapentadol hydrochloride extended-release</keyword>
	<keyword>JNS024ER</keyword>
	<keyword>Placebo</keyword>
</DOC>